Search - tctmd.com

Displaying 201 - 215 of 215

Sort: Relevancy | Date

News Industry News

Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension

July 28, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Daily News

IMPROVE-IT结果发布：对于向他汀类疗法中添加依泽替米贝是否有帮助进行了热烈的辩论

Yael L. Maxwell

June 05, 2015

News Daily News

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Yael L. Maxwell

June 05, 2015

News Daily News

El Controvertido Ezetimibe Ayuda cuando se Incorpora al Tratamiento con Estatinas

Yael L. Maxwell

June 05, 2015

Presentation

Ezetimibe Added to Statin Therapy After ACS

Presenter: Christopher P. Cannon

June 04, 2015

News Daily News

Poor Responders to Statins at Risk for CAD Progression

March 11, 2015

News Industry News

New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe-simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

February 24, 2015

News Conference News AHA 2014

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

November 16, 2014

News Industry News

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

August 25, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Industry News

Phase 3 Pivotal Data on Amgen's Novel Investigational Cholesterol-Lowering Medicine to be Featured at the American College of Cardiology's 63rd Annual Scientific Session

March 24, 2014

News Conference News ESC 2012

Niacin Holds No Surprise Side Effects But Efficacy Data Forthcoming

Caitlin E. Cox

August 26, 2012

News Daily News

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

May 27, 2011

Advertisement

Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

IMPROVE-IT结果发布：对于向他汀类疗法中添加依泽替米贝是否有帮助进行了热烈的辩论

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

El Controvertido Ezetimibe Ayuda cuando se Incorpora al Tratamiento con Estatinas

Ezetimibe Added to Statin Therapy After ACS

Poor Responders to Statins at Risk for CAD Progression

New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe-simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

Phase 3 Pivotal Data on Amgen's Novel Investigational Cholesterol-Lowering Medicine to be Featured at the American College of Cardiology's 63rd Annual Scientific Session

Niacin Holds No Surprise Side Effects But Efficacy Data Forthcoming

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content